G2GBIO Inc
456160
Company Profile
Business description
G2GBIO Inc is a Biotechnology company. The company manages Drug Delivery System platform company. The company possesses microsphere source technology (InnoLAMP) for the development of sustained-release pharmaceuticals, and development a demand for extended-half-life drugs, as well as world-class mass production processes and facilities.
Contact
21 Medical Complex-gil
Osong-eup
Heungdeok-gu
Chungcheongbuk-do
Cheongju-si
KORT: +82 432706000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
48
Stocks News & Analysis
stocks
Chart of the Week: CGT reform strengthens the case for dividend investing
Why dividend stocks are gaining an edge after tax reform.
stocks
Finding ASX opportunities in lofty market conditions
A widening valuation gap is revealing more discounted ASX shares with moats.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,122.70 | 62.80 | -0.68% |
| CAC 40 | 8,485.64 | 77.37 | 0.92% |
| DAX 40 | 25,612.03 | 151.55 | 0.60% |
| Dow JONES (US) | 52,126.52 | 532.38 | 1.03% |
| FTSE 100 | 10,897.27 | 11.14 | -0.10% |
| HKSE | 25,858.88 | 50.96 | 0.20% |
| NASDAQ | 25,073.34 | 630.40 | 2.58% |
| Nikkei 225 | 61,867.43 | 433.24 | 0.71% |
| NZX 50 Index | 13,762.78 | 213.89 | -1.53% |
| S&P 500 | 7,422.61 | 106.46 | 1.46% |
| S&P/ASX 200 | 8,967.70 | 57.10 | -0.63% |
| SSE Composite Index | 3,804.69 | 23.78 | -0.62% |